James Larkin
Royal Marsden NHS Foundation Trust · 1,132 works · 129,137 citations · h-index 127
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma